Gubra Past Earnings Performance
Past criteria checks 0/6
Gubra's earnings have been declining at an average annual rate of -92.7%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 10% per year.
Key information
-92.7%
Earnings growth rate
-124.4%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | 10.0% |
Return on equity | -10.0% |
Net Margin | -20.8% |
Next Earnings Update | 28 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gubra makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 224 | -47 | 86 | 97 |
31 Mar 24 | 214 | -46 | 80 | 93 |
31 Dec 23 | 205 | -45 | 75 | 89 |
30 Sep 23 | 204 | -26 | 73 | 83 |
30 Jun 23 | 204 | -7 | 71 | 77 |
31 Mar 23 | 201 | -1 | 69 | 67 |
31 Dec 22 | 199 | 4 | 67 | 57 |
31 Dec 21 | 255 | 68 | 52 | 27 |
31 Dec 20 | 172 | 13 | 45 | 34 |
Quality Earnings: PI3 is currently unprofitable.
Growing Profit Margin: PI3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PI3 is unprofitable, and losses have increased over the past 5 years at a rate of 92.7% per year.
Accelerating Growth: Unable to compare PI3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PI3 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.7%).
Return on Equity
High ROE: PI3 has a negative Return on Equity (-10.03%), as it is currently unprofitable.